Werewolf Therapeutics, Inc.
ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF

Last updated:

Abstract:

The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g. a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.

Status:
Application
Type:

Utility

Filling date:

22 Sep 2020

Issue date:

6 May 2021